


## LTL-448 datasheet

<b>Origin</b>	Metastatic human breast cancer	<b>Histopathology</b>	Metastatic infiltrating ductal carcinoma of the breast
<b>Year of establishment</b>	2012	<b>Doubling time</b>	8-10 days (subrenal capsule graft site)
<b>Local invasion</b>	Yes	<b>Metastasis</b>	Yes

The LTL-448 tumor line (Fig. 1) was developed from metastatic cells found in malignant pleural effusion of a patient with infiltrating ductal carcinoma of the breast. It grows well subcutaneously or at the sub-renal capsule graft site. When grafted at the renal capsules site, the LTL-448 line shows local invasion to adjacent host kidney and metastases to distant organs of the host.



### Genetic and epigenetic characteristics

Tumor line tissue (in tissue microarrays) for IHC and ISH is in place for screening potential targets upon request.

## **Applications**

1. Preclinical evaluation of established and potential anticancer drugs. Examination of drug efficacy on tumor growth, cell death (apoptosis, necrosis), tissue invasion, metastasis and angiogenesis.
2. Discovery of potential therapeutic targets and/or biomarkers for drug sensitivity.
3. Study of mechanisms underlying tumor growth, progression and metastasis.

**For more information, please contact us by email: [LTL@bccrc.ca](mailto:LTL@bccrc.ca) or phone: (604) 675 8013**